Posted on 03 February 2015

Theravance Biopharma and Mylan announced that the two companies will partner on the development and, subject to FDA approval, commercialization of TD-4208, a novel investigational once-daily nebulized long-acting muscarinic antagonist for chronic obstructive pulmonary disease and other respiratory diseases. Read the full story

Posted on 02 February 2015

Mylan has, through its Indian subsidiary Mylan Laboratories Limited, signed a definitive agreement to acquire certain female health care businesses from Famy Care Limited, a specialty women's health care company with global leadership in generic oral contraceptive products for $750 million in cash plus additional contingent payments of up to $50 million. Read the full story